Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

PFE Quantitative Stock Analysis June 24, 2025 — 09:39 am EDT. Written by John Reese for Validea-> Below is Validea's guru fundamental report for PFIZER INC . Of ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

The Pfizer stock's long-term trajectory looks predominantly bullish, as indicated in the quarterly chart. A closer look shows that between 1999 and 2009, there was a clear emergence of a bull flag ...

Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

See our analysis on Pfizer Stock Chances of Rise for more details. Even if we were to look at our Pfizer’s Valuation, with an EPS estimate of around $4.40 and a P/E multiple of around 13x in ...